I Have A Question About Antifosfolipid Antibodies And Its Treatment
Question: hello doctor !
1. As you are expert i m going to ask you - question about antifosfolipid antibodies and its its treatment
For example with Chronic Lyme disease - antifosfolipid antibodies are up and symptoms fatigue, malaise, headache and joint pain - as in understand in such case there should be treatment with hydroxychloroquine, to treat symptoms and prevent thrombosis events !
Upon re-evaluation for symmetric joint disease
the following positive results were found: LAC,
aCL IgM of 22 (normal <20), anti-b2GP1 IgM of
30 (normal <20) and antinuclear antibody (ANA)
(1:40). Treated with hydroxychloroquine, she
recovered.
https://sci-hub.se/10.1177/0000
And also in HCV antifosfolipid antibodies should be treated with hydroxychloroquine to prevent thrombosis events
https://sci-hub.se/https://doi.org/10.1177/0000
So it is recommended to screen antifosfolipid antibodies after infection and if they are up they should be treated before thrombosis events ?
2. Can antifosfolipid antibodies level reduction treatment with hydroxychloroquine before first thrombosis events reduce thrombosis risk in same level as in general population ?
3. Can i stop hydroxychloroquine treatment if my antifosfolipid antibodies are in 0 level, and i have no symptoms and have no thrombosis events before !
It seams logic that i can !
Thank you very much
1. As you are expert i m going to ask you - question about antifosfolipid antibodies and its its treatment
For example with Chronic Lyme disease - antifosfolipid antibodies are up and symptoms fatigue, malaise, headache and joint pain - as in understand in such case there should be treatment with hydroxychloroquine, to treat symptoms and prevent thrombosis events !
Upon re-evaluation for symmetric joint disease
the following positive results were found: LAC,
aCL IgM of 22 (normal <20), anti-b2GP1 IgM of
30 (normal <20) and antinuclear antibody (ANA)
(1:40). Treated with hydroxychloroquine, she
recovered.
https://sci-hub.se/10.1177/0000
And also in HCV antifosfolipid antibodies should be treated with hydroxychloroquine to prevent thrombosis events
https://sci-hub.se/https://doi.org/10.1177/0000
So it is recommended to screen antifosfolipid antibodies after infection and if they are up they should be treated before thrombosis events ?
2. Can antifosfolipid antibodies level reduction treatment with hydroxychloroquine before first thrombosis events reduce thrombosis risk in same level as in general population ?
3. Can i stop hydroxychloroquine treatment if my antifosfolipid antibodies are in 0 level, and i have no symptoms and have no thrombosis events before !
It seams logic that i can !
Thank you very much
Brief Answer:
Yes you can
Detailed Answer:
Hello,
I can understand your concern.In general anti phospholipid syndrome is more risky in females especially if they want to get pregnant in which period the thrombosis is at a high risk to happen and it is life threatening.
In males if the level of antibodies are low or 0 yes you can discontinue the treatment
For the first question you can not compare the risk with the normal population because it is not correct.
However in general the patients with this syndrome it is well known that are in high risk to do thrombosis unfortunately
Hope to have been helpful
Regards
Dr.Jolanda
Yes you can
Detailed Answer:
Hello,
I can understand your concern.In general anti phospholipid syndrome is more risky in females especially if they want to get pregnant in which period the thrombosis is at a high risk to happen and it is life threatening.
In males if the level of antibodies are low or 0 yes you can discontinue the treatment
For the first question you can not compare the risk with the normal population because it is not correct.
However in general the patients with this syndrome it is well known that are in high risk to do thrombosis unfortunately
Hope to have been helpful
Regards
Dr.Jolanda
Note: For further follow up on related General & Family Physician Click here.
Above answer was peer-reviewed by :
Dr. Dr. Yogesh D